Skip to main navigation Skip to search Skip to main content

Nonsurgical periodontal treatment in type II diabetics in a middle-income country: a cost-effectiveness analysis

  • Ana M. Rojas-Gómez
  • , Juan J. Serrano
  • , Diego Rosselli
  • Epistemonikos Foundation
  • Universidad del Magdalena
  • Universidad Javeriana

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Objectives: To evaluate the cost-effectiveness of the nonsurgical periodontal treatment (NSPT) compared with supragingival therapy in type II diabetics with periodontitis. Methods: A decision tree analysis was used to estimate the costs and health outcomes of two periodontal therapies in a hypothetical cohort of type II diabetics with periodontitis. The analysis was developed from the perspective of a third-party payer at 1 year and 5 years. Probabilities were derived from two systematic reviews. The costs and resource use were validated by a Delphi expert panel. All costs were expressed in USD, using the 25 May 2021 Colombian pesos market exchange rate (USD 1 = COP 3,350). Results: NSPT was a dominant alternative compared with subsidized supragingival therapy in type II diabetics with periodontitis, generating savings of USD 87 and 400, during the first year or up to 5 years, respectively, and improving dental survival from 32 to 69 percent. Conclusions: NSPT can generate savings by reducing the complications derived from uncontrolled periodontitis and tooth loss.

Original languageEnglish
Article numbere73
JournalInternational journal of technology assessment in health care
Volume38
Issue number1
DOIs
StatePublished - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • cost-effectiveness analysis
  • diabetes
  • non-surgical periodontal treatment
  • periodontal therapy
  • periodontitis

Fingerprint

Dive into the research topics of 'Nonsurgical periodontal treatment in type II diabetics in a middle-income country: a cost-effectiveness analysis'. Together they form a unique fingerprint.

Cite this